The presentation will cover the landmark chemoimmunotherapy trials including FCR (CLL8) and BR (Eichorst, et al. Lancet. 2016). In addition, the landmark studies for the novel front-line agents will be reviewed for ibrutinib (RESONATE-2, ALLIANCE, iLLUMINATE, E1912), acalabrutinib (ELEVATE-TN), and venetoclax (CLL14). After the clinical trials are summarized, toxicity and administration of these front-line treatments will be reviewed to fulfil the second objective. Before transitioning into upcoming clinical data, a patient case(s) will be used to assess the audiences understanding of picking a front-line agent based on specific patient factors. Lastly, CLL remains a rapidly evolving field with many upcoming trials that have the potential to significantly impact front-line treatment of CLL. This will be highlighted in the CAPTIVATE study (ibrutinib + venetoclax), AVO regimen (acalabrutinib + venetolcax + obinutuzumab), LOXO-305, zanubrutinib, and ublituximab/umbralisib. Less time will be spent on the specifics of these clinical trials since only preliminary data is available from ASH. The third objective goal is to highlight the evolving treatment schema that involves novel treatment only, utilizes a time-definitive treatment approach, and targets early MRD negativity.
Pharmacist Learning Objectives
-
Compare and contrast the recommended front-line regimens for the treatment of chronic lymphocytic leukemia (CLL)
-
Recognize patient-specific characteristics in the selection of an appropriate front-line treatment regimen for CLL
-
Identify upcoming clinical trials and the potential impact on selection of front-line treatment
Nurse Learning Objectives
-
Compare and contrast the recommended front-line regimens for the treatment of chronic lymphocytic leukemia (CLL)
-
Recognize patient-specific characteristics in the selection of an appropriate front-line treatment regimen for CLL
-
Identify upcoming clinical trials and the potential impact on selection of front-line treatment
Charlene Kabel,
PharmD, BCOP
Clinical Pharmacy Specialist - Leukemia, Memorial Sloan Kettering Cancer Center, New York, NY
0798-0000-20-114-L01-P (Application-Based)
0798-0000-20-114-L01-N (Application-Based)
Supported By
Novartis, Pharmacyclics and Janssen